Metformin anti-proliferative effect on a cohort of non-diabetic breast cancer patients

The effect of metformin on biomarkers associated with breast cancer outcomes: a systematic review, meta-analysis, and dose–response of randomized clinical trials

“…We excluded 179 articles and retrieved 18 poten-tially relevant studies for full-text assessment of eligibility. Eight articles (9 studies) [31][32][33][34][35][36][37][38] fulfilled the inclusion cri-teria and were included in the metaanalysis. Nine articles were excluded for the following reasons: (1) no RCT design (n = 3), (2) no human trial (n = 5), and (3) no placebo (n = 2).…”

“…Two studies were judged to have fair quality [31,33] (Table 2), three poor quality [34,35,38], and have good quality [32,36,37]. Most studies were judged to be of poor quality due to inadequate randomization techniques and blinding of participants as well as assessors.…”

The Effect of Metformin on Survival Outcomes of Non-Metastatic Breast Cancer Patients with Type 2 Diabetes

“…The role of metformin in earlystage breast cancer was assessed in non-diabetic women in support of the significant effect of metformin on the reduction of tumor proliferation and increase of apoptosis (Niraula et al, 2012). On the other hand, some clinical window of opportunity studies that explored metformin's effects on non-diabetic patients showed a significant reduction of Ki67 marker in accordance with its effect on glucose and insulin levels (Homeostasis Model Assessment score) (Sadighi et al, 2016). A basic research, through an in vitro study, using breast cancer cell lines of four different subtypes (Luminal-A, luminal-B, HER2 type and TNBC) in normoglycemic settings, failed to show added neoadjuvant value for metformin when compared to a taxane agent alone (Sadighi et al, 2014).…”

A precision medicine approach to metabolic therapy for breast cancer in mice

“…Metformin is safe and shows good target engagement in women with breast cancer. Studies regarding its efficacy, however, have been mixed, with most 23 – 29 , but not all, adjuvant and neoadjuvant studies 30 – 32 failing to observe differences in tumor cell proliferation markers or in outcomes in human patients.…”